Patient data is the lifeblood of a clinical trial, but the eCOA/ePRO market has yet to live up to the promise of engaging more patients. Sponsors and CROs should expect more. We need an objective look at where the market is lagging, and concrete steps we can take to improve.
- Describe why a legacy eCOA/ePRO system will not deliver the same results as a system developed with modern, digital technology
- Examine how eCOA/ePRO technologies should promote compliance by giving patients apps that are akin to apps they use in daily life, on their own devices
- Discuss how eCOA/ePRO will not become a strategic component of sponsor and CROs technology portfolios unless vendors embrace continuous innovation